These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 33466831)
21. Impaired Photic Entrainment of Spontaneous Locomotor Activity in Mice Overexpressing Human Mutant α-Synuclein. Pfeffer M; Zimmermann Z; Gispert S; Auburger G; Korf HW; von Gall C Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29865270 [TBL] [Abstract][Full Text] [Related]
22. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease. Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034 [TBL] [Abstract][Full Text] [Related]
23. Genetic deletion of nitric oxide synthase 2 ameliorates Parkinson's disease pathology and neuroinflammation in a transgenic mouse model of synucleinopathy. Kim J; Han JY; Lee Y; Kim K; Choi YP; Chae S; Hoe HS Mol Brain; 2023 Jan; 16(1):7. PubMed ID: 36647152 [TBL] [Abstract][Full Text] [Related]
24. NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease. Sirabella R; Sisalli MJ; Costa G; Omura K; Ianniello G; Pinna A; Morelli M; Di Renzo GM; Annunziato L; Scorziello A Cell Death Dis; 2018 Jun; 9(7):725. PubMed ID: 29941946 [TBL] [Abstract][Full Text] [Related]
25. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease. Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303 [TBL] [Abstract][Full Text] [Related]
27. Accelerated accumulation of retinal α-synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson's disease. Mammadova N; Summers CM; Kokemuller RD; He Q; Ding S; Baron T; Yu C; Valentine RJ; Sakaguchi DS; Kanthasamy AG; Greenlee JJ; Heather West Greenlee M Neurobiol Dis; 2019 Jan; 121():1-16. PubMed ID: 30218757 [TBL] [Abstract][Full Text] [Related]
28. Orexins alleviate motor deficits via increasing firing activity of pallidal neurons in a mouse model of Parkinson's disease. Wang Y; Chen AQ; Xue Y; Liu MF; Liu C; Liu YH; Pan YP; Diao HL; Chen L Am J Physiol Cell Physiol; 2019 Oct; 317(4):C800-C812. PubMed ID: 31365289 [TBL] [Abstract][Full Text] [Related]
29. Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson's disease. Yang J; Luo S; Zhang J; Yu T; Fu Z; Zheng Y; Xu X; Liu C; Fan M; Zhang Z Neurobiol Dis; 2021 Jan; 148():105218. PubMed ID: 33296726 [TBL] [Abstract][Full Text] [Related]
30. Neurodegeneration and contralateral α-synuclein induction after intracerebral α-synuclein injections in the anterior olfactory nucleus of a Parkinson's disease A53T mouse model. Flores-Cuadrado A; Saiz-Sanchez D; Mohedano-Moriano A; Martinez-Marcos A; Ubeda-Bañon I Acta Neuropathol Commun; 2019 Apr; 7(1):56. PubMed ID: 30987677 [TBL] [Abstract][Full Text] [Related]
31. MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian. Mo M; Xiao Y; Huang S; Cen L; Chen X; Zhang L; Luo Q; Li S; Yang X; Lin X; Xu P Oncotarget; 2017 Jan; 8(1):15-28. PubMed ID: 27965467 [TBL] [Abstract][Full Text] [Related]
32. Sex-dependent effects of monomeric α-synuclein on calcium and cell death of lateral hypothalamic mouse neurons are altered by orexin. Bohid S; Ali LK; Romero-Leguizamón CR; Langkilde AE; Dos Santos AB; Kohlmeier KA Mol Cell Neurosci; 2024 Jun; 129():103934. PubMed ID: 38701995 [TBL] [Abstract][Full Text] [Related]
33. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254 [TBL] [Abstract][Full Text] [Related]
34. Orexin pathway in Parkinson's disease: a review. Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Zaafar D; Batiha GE Mol Biol Rep; 2023 Jul; 50(7):6107-6120. PubMed ID: 37155018 [TBL] [Abstract][Full Text] [Related]
35. Retinal hyperspectral imaging in mouse models of Parkinson's disease and healthy aging. Trlin P; Gong J; Tran KKN; Wong VHY; Lee PY; Hoang A; Zhao D; Beauchamp LC; Lim JKH; Metha A; Barnham KJ; Finkelstein DI; Bui BV; Bedggood P; Nguyen CTO Sci Rep; 2024 Jul; 14(1):16089. PubMed ID: 38997314 [TBL] [Abstract][Full Text] [Related]
37. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Fishbein I; Kuo YM; Giasson BI; Nussbaum RL Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739 [TBL] [Abstract][Full Text] [Related]
38. A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. Kurz A; May C; Schmidt O; Müller T; Stephan C; Meyer HE; Gispert S; Auburger G; Marcus K J Neural Transm (Vienna); 2012 Mar; 119(3):297-312. PubMed ID: 21960009 [TBL] [Abstract][Full Text] [Related]
39. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease. Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974 [TBL] [Abstract][Full Text] [Related]
40. Transgenic Archaerhodopsin-3 Expression in Hypocretin/Orexin Neurons Engenders Cellular Dysfunction and Features of Type 2 Narcolepsy. Williams RH; Tsunematsu T; Thomas AM; Bogyo K; Yamanaka A; Kilduff TS J Neurosci; 2019 Nov; 39(47):9435-9452. PubMed ID: 31628177 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]